Oxford Biomedica plc (OXBDF) Q4 2024 Earnings Call Transcript

2025-04-09 11:28:13 ET

Oxford Biomedica plc (OXBDF)

Q4 2024 Earnings Conference Call

April 09, 2025 08:00 AM ET

Company Participants

Frank Mathias - Chief Executive Officer

Sebastien Ribault - Chief Business Officer

Lucy Crabtree - Chief Financial Officer

Conference Call Participants

Charles Weston - RBC Capital Markets

Andy Smith - Equity Development

John Priestner - JPMorgan

Jens Lindqvist - Investec

Rick Bienkowski - Cantor Fitzgerald

Presentation

Frank Mathias

So, good afternoon to everyone here in London, and also good morning to those who are joining us from overseas. Thank you for attending this call today, our analyst briefing for our 2024 Preliminary Results. It's great to see so many people here in the room, known faces. Thank you for joining. But we have also a few people joining virtually. So, hello to everyone again.

Presenting with me today, we have our Chief Financial Officer, Dr. Lucy Crabtree, who started to join us in September last year and has already made a significant impact during this short period. I'm also pleased to welcome our Chief Business Officer, Dr. Sebastien Ribault. You are known, I believe, well here, and a lot of you are familiar with him.

So disclaimer. Before we dive in, let's start with our agenda for today. As you can see, we will start with an overview of the key achievements across the business, highlighting what sets up OXB apart from our peers and how our differentiated pure play CDMO strategy in cell and gene therapy continues to drive our success. I will then hand over to Sebastian to provide us an update on the strong momentum we are seeing on the commercial side. And then, Lucy will take us through our financial performance before handing back to me to wrap up ahead of the Q&A session.

This is a nice slide. I would like to start by highlighting some of the key figures, which demonstrates OXB's outstanding financial performance in 2024. The company has achieved an impressive organic revenue growth of 81%, with total revenues increasing by 44% to nearly GBP130 million. During 2024, our team grew the pipeline by 30% to -- and this is in dollar, $570 million and increased customer orders by 35% to, in again, GBP186 million. We also delivered an EBITDA profit in the second half of the year. This strong business momentum, fueled by growing order book and pipeline reinforces our confidence in achieving both attractive growth and sustainable profitability in line with our forecast. These are all remarkable achievements in 2024.

So, let me now elaborate on the successful execution on our pure play CDMO strategy, which we have started more than one year ago. By integrating our global activities, we have improved our client service, unlocked operational synergies, and strengthened our position as a differentiated multi-vector, multi-site CDMO. In January last year, we completed the acquisition of OXB in France, formerly ABL Europe, expanding our operational footprint and ability to meet growing demand across Europe. Less than a year later, we successfully enabled antiviral vector development and manufacturing capabilities at our France sites, complementing the offering of our facilities in the UK and US....

Read the full article on Seeking Alpha

For further details see: